
June 23 (Reuters) - Amgen Inc AMGN.O:
RESULTS FROM AMGEN'S PHASE 2 OBESITY STUDY OF MONTHLY MARITIDE PRESENTED AT THE AMERICAN DIABETES ASSOCIATION 85TH SCIENTIFIC SESSIONS
AMGEN - IN PEOPLE LIVING WITH OBESITY WITH TYPE 2 DIABETES, MARITIDE DEMONSTRATED UP TO ABOUT 17% AVERAGE WEIGHT LOSS AND ROBUST HBA1C IMPROVEMENTS
AMGEN INC - MARITIDE SHOWS ABOUT 20% WEIGHT LOSS IN OBESITY WITHOUT T2D
AMGEN INC - MARITIME PHASE 3 CHRONIC WEIGHT MANAGEMENT STUDIES ARE ACTIVELY ENROLLING
AMGEN- PHASE 3 STUDIES IN PEOPLE LIVING WITH ATHEROSCLEROTIC CARDIOVASCULAR DISEASE, HEART FAILURE AND OBSTRUCTIVE SLEEP APNEA TO BE INITIATED IN 2025